Bioventix (BVXP)

 

BVXP Share PerformanceMore

52 week high1,850.0 05/04/17
52 week low899.5 25/07/16
52 week change 782.5 (75.79%)
4 week volume124,690 02/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii BIOVENTIX PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal o...

Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Bioventix (Sedol B4QVDF0 ) 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial instrum...

Issue of Equity

Bioventix plc (?Bioventix? or ?the Company?) Issue of Equity Bioventix plc (BVXP) a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has applied for 40,018 ordinary shares of 5 pence each (the ?Option Shares?) to be admitted to trading on AIM (?Adm...

Broker Forecast - finnCap issues a broker note on Bioventix Plc

finnCap today reaffirms its corporate investment rating on Bioventix Plc (LON:BVXP) and raised its price target to 1750p ...

Bioventix pre-tax profits rise

Bioventix's pre-tax profits rose by 49% to 2.48m in the six months to the end of December. Turnover rose by 32% to 3.12m a...

Interim Results

Bioventix plc UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2016 Bioventix plc (BVXP) (?Bioventix? or ?the Company?), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim financial results for t...

10 fast-paced growth stocks for all traders

Now is a great time to be a stock trader, argues Mark Minervini, a former US Investing Champion. Stockopedia's Ben Hobs...

Five shares for the watchlist

Companies analyst Richard Beddard trawls through corporate results to pick great stocks for his portfolio. Here he profiles...

Fundamental DataMore

P/E ratio26.236
EPS69.18
Dividend yield2.342 %

Latest discussion posts More

  • Re: Interims

    Just to add to my post, Bioventix's figures in recent years have not been skewed by exceptional items. If one looks at the fundamentals page & the bar charts for sales, profit, ...
    27-Mar-2017
    Hardboy
  • Re: Interims

    And they look excellent. Sales up 32%. Profits up 49%. Net Cash pile growing. Dividend up 21%. This really is a remarkable business.
    27-Mar-2017
    Hardboy
  • Re: Interims

    You are correct - just had confirmation from finnCap to that effect
    22-Mar-2017
    charlie51

Users' HoldingsMore

Users who hold Bioventix also hold..
SOMERO ENTER DI27%
LLOYDS GRP.27%
GLAXOSMITHKLINE24%
BURFORD CAP LD22%
OPTIBIOTIX H.20%

Codes & Symbols

ISINGB00B4QVDF07
SymbolsBVXP, LSE:BVXP, BVXP.L, BVXP:LN, LON:BVXP, XLON:BVXP